Latest Conference Articles

March 19th 2016, 1:25pm

SGO Annual Meeting

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival outcomes versus patients without HR mutations.

March 19th 2016, 12:29pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

March 19th 2016, 11:03am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.

March 18th 2016, 1:11pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.

March 18th 2016, 12:42pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

A host of novel agents are on the horizon that could further improve the long-term outcomes experienced by patients with follicular lymphoma, particularly those with relapsed or refractory disease.

March 18th 2016, 11:58am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Kareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemia‎ (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.

March 18th 2016, 7:53am

PER® Miami Breast Cancer Conference

Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

March 18th 2016, 5:50am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

March 18th 2016, 5:00am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Shaji Kumar, MD, discusses how the phase III SWOG S0777 study, which investigated the combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, significantly changed the frontline treatment paradigm for patients with multiple myeloma

March 14th 2016, 8:34am

PER® Miami Breast Cancer Conference

Elizabeth A. Mittendorf, MD, PhD, discusses nelipepimut-S (NeuVax), a peptide derived from HER2 protein combined with granulocyte-macrophage colonystimulating factor that is currently being investigated as a single-agent, in combination with standard-of-care therapies, and in multiple settings and subtypes of breast cancer.

March 13th 2016, 4:15pm

PER® Miami Breast Cancer Conference

Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

March 13th 2016, 10:21am

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

March 13th 2016, 8:00am

PER® Miami Breast Cancer Conference

There is a subset of low-risk patients with ductal carcinoma in situ for whom surgery alone is optimal and the Oncotype DX DCIS Score is a useful assay for identifying these individuals.

March 13th 2016, 8:00am

PER® Miami Breast Cancer Conference

A number of crucial findings were presented over the course of 2015 that helped to characterize an ever-growing trend toward personalized medicine in the treatment of breast cancer.

March 13th 2016, 6:00am

PER® Miami Breast Cancer Conference

Pathologic complete response may still have a role in accelerated neoadjuvant approvals for select patients with early stage breast cancer, despite the fact that it remains an unproven surrogate endpoint.

March 12th 2016, 5:35pm

PER® Miami Breast Cancer Conference

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

March 12th 2016, 3:49pm

PER® Miami Breast Cancer Conference

Amy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.

March 12th 2016, 1:25pm

PER® Miami Breast Cancer Conference

Breast cancer survivor and Good Morning America news anchor Amy Robach delivered a compelling keynote address at the 33rd Annual Miami Breast Cancer Conference®.

March 12th 2016, 12:41pm

PER® Miami Breast Cancer Conference

The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.

March 12th 2016, 8:55am

PER® Miami Breast Cancer Conference

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.